March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Ranibizumab for Idiopathic Epiretinal Membranes: a Prospective Evaluation
Author Affiliations & Notes
  • Michel J. Belliveau
    Ophthalmology, Queen's University, Kingston, Ontario, Canada
  • Marwan Abouammoh
    Ophthalmology, Queen's University, Kingston, Ontario, Canada
  • David R. Almeida
    Ophthalmology, Queen's University, Kingston, Ontario, Canada
  • Sanjay Sharma
    Ophthalmology, Queen's University, Kingston, Ontario, Canada
  • Jeffrey Gale
    Ophthalmology, Queen's University, Kingston, Ontario, Canada
  • Footnotes
    Commercial Relationships  Michel J. Belliveau, None; Marwan Abouammoh, None; David R. Almeida, None; Sanjay Sharma, Novartis, Genentech (C); Jeffrey Gale, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5193. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michel J. Belliveau, Marwan Abouammoh, David R. Almeida, Sanjay Sharma, Jeffrey Gale; Ranibizumab for Idiopathic Epiretinal Membranes: a Prospective Evaluation. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5193.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the effect of ranibizumab on idiopathic epiretinal membranes (ERM).

Methods: : Consecutive patients with idiopathic ERM were offered a series of intravitreal ranibizumab injections. Patients received three to six 0.05mg/0.1ml injections at monthly intervals. The primary outcome measure was central macular thickness (CMT) measured by spectral-domain OCT. Change in best-corrected visual acuity (VA) was assessed at distance and near.

Results: : Eleven patients (age 58-81, mean 70.6) were followed for 7 months with at least 1month follow-up after the final injection. There was a statistically significant but clinically insignificant reduction in CMT (mean difference 8 microns, 95% CI 0.06-16.12 p=0.049). ETDRS VA showed a mean gain of only 3 letters (p=0.083), and near VA showed a statistically significant improvement (mean logMAR from 0.25 to 0.16, p=0.001). There were no complications.

Conclusions: : Despite the presence of vascular endothelial growth factor and receptors for this molecule in idiopathic ERM, a series of 3-6 monthly injections of ranibizumab does not appear to have an effect as a sole treatment.

Clinical Trial: : http://www.clinicaltrials.gov NCT01238393

Keywords: macula/fovea • retina • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×